Researchers synthesizing new, first-in-class drug to stop growth of ER-positive breas
Researchers at UT Health San Antonio and two partner institutions are developing a new, first-in-class agent that has stopped the growth of estrogen receptor-positive (ER-positive) breast cancer in its tracks.